|
|
| Line 1: |
Line 1: |
| {|class="wikitable" style="width:80%"
| | ==2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure== |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| | |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' For patients at risk of developing HF, natriuretic peptide biomarker–based screening followed by team- based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset HF ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki>
| |
| |}
| |
| | |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Routine combined use of an [[ACEIs|ACE inhibitor]], [[Angiotensin II receptor blockers|ARB]], and [[aldosterone antagonist]] is not recommended for patients with current or prior symptoms of [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
| |
| |}
| |
| | |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightCoral; ; width: 300px"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm)
| |
| |-
| |
| | bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|ARNI]] should not be administered concomitantly with [[ACE inhibitor|ACE inhibitors]] or within 36 hours of the last dose of an ACE inhibitor. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|ARNI]] should not be administered to patients with a history of [[angioedema]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-EO]])'' <nowiki>"</nowiki>
| |
| |}
| |
| | |
| | |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Angiotensin II receptor blockers]] are reasonable to use as alternatives to [[ACEIs|ACE inhibitors]] as first-line therapy for patients with mild to moderate [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]), especially for patients already taking [[Angiotensin II receptor blockers|ARBs]] for other indications.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki>
| |
| |}
| |
| | |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
| |
| |-
| |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Angiotensin II receptor blockers]] are reasonable to use as alternatives to [[ACEIs|ACE inhibitors]] as first-line therapy for patients with mild to moderate [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]), especially for patients already taking [[Angiotensin II receptor blockers|ARBs]] for other indications.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki>
| |
| |}
| |